Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. Efgartigimod alfa is a neonatal Fc receptor blocker...
17 KB (1,326 words) - 07:06, 25 June 2024
Efgartigimod alfa/hyaluronidase, sold under the brand name Vyvgart Hytrulo, is a coformulation medication used for the treatment of generalized myasthenia...
6 KB (425 words) - 07:18, 25 June 2024
carefully selected cases. Efgartigimod alfa (Vyvgart) was approved for medical use in the United States in December 2021. Efgartigimod alfa/hyaluronidase (Vyvgart...
82 KB (8,919 words) - 21:01, 2 November 2024
L04AA40 Cladribine L04AA41 Imlifidase L04AA48 Belumosudil L04AA58 Efgartigimod alfa L04AB01 Etanercept L04AB02 Infliximab L04AB03 Afelimomab L04AB04 Adalimumab...
3 KB (367 words) - 15:37, 25 January 2024
line of therapy including lenalidomide and a proteasome inhibitor. Efgartigimod alfa/hyaluronidase (Vyvgart Hytrulo) was approved for the treatment of...
34 KB (3,092 words) - 05:38, 14 September 2024
Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis". Argenx. 17 December 2021...
36 KB (4,071 words) - 16:46, 6 April 2024
Deucravacitinib Deuruxolitinib Dimethyl fumarate Diroximel fumarate Efgartigimod alfa (+hyaluronidase) Etrasimod Filgotinib Fingolimod Guselkumab Iptacopan...
7 KB (299 words) - 13:45, 27 April 2024
Deucravacitinib Deuruxolitinib Dimethyl fumarate Diroximel fumarate Efgartigimod alfa (+hyaluronidase) Etrasimod Filgotinib Fingolimod Guselkumab Iptacopan...
38 KB (2,656 words) - 20:26, 6 November 2024